PET scan for neuroendocrine tumors
Part of Cancer clinical trials.
This study uses a special PET scan called 18F-AlF-NOTA-Octreotide to get clear images of neuroendocrine tumors. It can help doctors see where the tumors are and how active they are, which may guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with or your doctor suspects you have a neuroendocrine neoplasm (a type of tumor that grows from hormone-producing cells).
- You are able to have a biopsy (a small tissue sample taken) or surgery.
- You do not have any other active cancer at this time.
- You do not have any severe uncontrolled medical conditions or active infections.
- You are capable of understanding and agreeing to the study by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
This trial compares two types of PET scans to see which one better detects neuroendocrine tumors (rare cancers that grow slowly in the body). You'll receive both scans to help doctors understand which imaging method works best.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.